Sofosbuvir

In patients with hepatitis C infection who failed treatment with Vosevi, retreatment with a regimen of Sovaldi plus Mavyret plus ribavirin for 16 to 24 weeks was safe and effective, researchers reported.

A simplified, rapid treatment model for hepatitis C virus improved cure rates and the cascade of care among young people who inject drugs, according to a recent study.

Sofosbuvir, mirabegron and nintedanib — all approved within the past 9 years — are among the drugs associated with the highest disproportionate reporting of ANCA-associated vasculitis, according to data.

Ravidasvir in addition to sofosbuvir was safe and effective in the treatment of patients with chronic hepatitis C virus, according to research published in The Lancet Gastroenterology and Hepatology.

A real-world analysis has shown that a test-and-treat approach coupled with treatment with Epclusa is feasible and results in high cure rates among incarcerated patients with hepatitis C.

In a comparison of two treatment models for HCV, researchers found that both were effective among people who injected drugs.

Despite little contact with providers, patients in a minimal monitoring scenario achieved ‘cure’ of their hepatitis C virus, according to a presentation at The Digital Liver Meeting Experience.

In a minimal monitoring – or “Minmon” – study, patients given a full regimen for hepatitis C virus and then remotely monitored achieved 95% sustained virologic response, according to a presenter at The Liver Meeting Digital Experience.

In this exclusive video, Joss O’Loan, MBBS, from the Hepatitis C Kombi Clinic in Brisbane, Australia, discusses two studies presented at The Digital International Liver Congress on HCV elimination programs using Epclusa.

Epclusa is now available for the treatment of children with any of the six genotypes of hepatitis C virus after obtaining approval from the FDA, according to a press release.